Unresectable Hepatocellular Carcinoma: Tislelizumab as Effective First-Line Alternative to Sorafenib
Medical Supporter — Avis d’information
Cet article est une synthèse d’informations médicales internationales et ne constitue pas un avis médical ; il ne remplace pas le diagnostic ni le plan de traitement de votre médecin traitant. Les informations présentées sont compilées à partir de publications publiques et de déclarations officielles d’établissements médicaux japonais ; l’adéquation et les résultats de toute thérapie varient selon chaque patient et doivent être évalués individuellement par un médecin qualifié.
RATIONALE 301 Phase III Clinical Trial Results
- September 2, 2022
- Reading time: 1 minute
On August 9, 2022, Beigene Ltd released a press statement announcing the results of the RATIONALE 301 Phase III clinical trial evaluating the efficacy and safety of tislelizumab monotherapy in treatment-naive patients with unresectable hepatocellular carcinoma, with overall survival as the primary efficacy endpoint.
Trial Design and Patient Population
RATIONALE 301 was an international, multi-institutional, randomized Phase III clinical trial enrolling patients with unresectable hepatocellular carcinoma. Patients were randomly assigned to:
- Tislelizumab Group
- Sorafenib Control Group
Primary endpoint: overall survival
Secondary endpoints: objective response rate, progression-free survival, and duration of response
Clinical Trial Results
Overall Survival - Primary Endpoint:
The tislelizumab group achieved overall survival outcomes that were non-inferior to the sorafenib control group, meeting the primary trial efficacy objective.
Safety Profile
The safety profile of tislelizumab was consistent with the established safety database from prior clinical trials. No novel or unexpected adverse events were identified in this trial.
Clinical Significance
According to Mark Lanasa, Chief Medical Officer of Beigene Ltd:
"Unresectable hepatocellular carcinoma represents a malignancy with generally poor prognosis, with median survival of approximately one year. A subset of patients cannot tolerate tyrosine kinase inhibitor-based approaches, thus restricting therapeutic options. The RATIONALE 301 trial demonstrates favorable clinical outcomes, with potential to establish tislelizumab as a new therapeutic option for this patient population."
Data Source
Beigene Ltd Press Release: https://ir.beigene.com/news-details/?id=65d92c44-3f6f-4a00-9433-52c144854bbc
Related Hepatocellular Carcinoma Treatment
- Immunotherapy
- Clinical Trial Therapeutics
- (Lung Cancer) Topotecan and Topotecan Plus Berzosertib Phase II Trial Results
- (Lung Cancer) HER2-Mutant Non-Small Cell Lung Cancer Treatment with Enhertu
- (Lung Cancer) Anti-B7-H3 Antibody DS-7300 Clinical Efficacy
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Vous envisagez des soins au Japon ? Besoin d’informations et d’aide ?
Nous vous aidons à rassembler les informations nécessaires pour un déplacement médical au Japon, à contacter les établissements japonais et à organiser une consultation de second avis.La première consultation est gratuite ; un conseiller vous aide à clarifier les prochaines étapes.
Figure 1
Figure 2
Figure 3
Figure 4